Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report issued on Thursday.

MCRB has been the subject of several other research reports. Chardan Capital reiterated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Trading Up 4.1 %

MCRB opened at $0.77 on Thursday. The firm has a market cap of $133.28 million, a P/E ratio of -3.33 and a beta of 2.19. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $1.53. The stock has a 50-day moving average of $0.81 and a 200 day moving average of $0.84.

Institutional Trading of Seres Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Avantax Advisory Services Inc. lifted its stake in Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 37,866 shares in the last quarter. Virtu Financial LLC raised its stake in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC raised its stake in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 22,250 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.